
|Articles|December 1, 2021
Daily Medication Pearl: Insulin Lispro Injection (Admelog)
Author(s)Saro Arakelians, PharmD
Admelog is indicated to improve glycemic control in type 1 and type 2 diabetes mellitus.
Advertisement
Medication Pearl of the Day: Insulin Lispro Injection (Admelog)
Indication: Admelog is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 3 years of age and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.
Insight:
- Dosing: Administer Admelog by subcutaneous injection within 15 minutes before or immediately after a meal.
- Dosage forms: 10 mL multiple-dose vials, 3 mL single patient use SoloStar prefilled pens.
- Adverse events: Adverse reactions associated with Admelog include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.
- Mechanism of action: Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
- Manufacturer: Sanofi-Aventis
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First At-Home Treatment Device for Depression
2
How Next-Generation CDK Inhibitors Are Redefining Post–CDK4/6 Therapy in HR+/HER2– Metastatic Breast Cancer
3
Automation and Standardization Take Center Stage in Health System’s Centralized IV Compounding Strategy
4
Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer
5


















































































































































































































